PMA device
Solesta (Injectable Gel)
Palette Life Sciences · Agent, Bulking, Injectable For Gastro-Urology Use (LNM, Class III) · First FDA decision May 27, 2011, newest Oct 27, 2021Overactive bladder and urinary incontinence
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
8
PMA pathway
Device trials
4
Naming "Solesta"
MAUDE reports
27
Brand "Solesta", since 2015
PubMed studies
9
Mentioning "Solesta"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Solesta (Injectable Gel)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 8 decisions filed under this name.
- Solesta (Injectable Gel)PMA supplement
P100014-S031 · Decided Oct 27, 2021 · 177 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- Solesta Injectable GelPMA supplement
P100014-S026 · Decided Oct 9, 2020 · 175 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- SOLESTA INJECTABLE GELPMA supplement
P100014-S017 · Decided Jan 21, 2015 · 63 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Older decisions: P100014-S004, P100014
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Solesta", any status and sponsor, newest update first.
Galderma R&DNot on our public-company list
NCT01110681 · 115 participants · Start Nov 2007 · Primary completion Nov 2009
Device: Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) · For: Fecal Incontinence
Sites: Vancouver, Canada; HUS, Finland; Nantes, France · 15 sites in all
- A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal IncontinencePivotal-lookingCompleted
Bausch Health Americas, Inc.Not on our public-company list
NCT00605826 · 206 participants · Start Sep 7, 2006 · Primary completion Nov 23, 2009
Device: NASHA/Dx (Solesta) Gel; Sham Injection · For: Fecal Incontinence
Sites: San Francisco, California; Tampa, Florida; Burlington, Massachusetts · 13 sites in all
Uppsala UniversityAcademic, hospital or other
NCT03746834 · 7 participants · Start Sep 20, 2013 · Primary completion Dec 12, 2015
Device: NASHA/Dx (Solesta®) · For: Fecal Incontinence; Anorectal Malformation
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Solesta", and for the whole product code for context.
This brand
27 reports: 8 malfunction, 19 injury, 0 death
Whole product code LNM
544 reports: 170 malfunction, 369 injury, 2 death
Newest reports for this brand
- SOLESTA INJECTABLE GELInjury
3014909464-2025-00064 · Received Dec 3, 2025 · Event dated Nov 3, 2025
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Abscess
- SOLESTA INJECTABLE GELInjury
3014909464-2025-00052 · Received Oct 10, 2025 · Event dated Sep 17, 2025
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Cyst(s); Discomfort
- SOLESTA INJECTABLE GELInjury
3014909464-2025-00043 · Received Sep 29, 2025 · Event dated Sep 2, 2025
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Fever; Constipation
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Solesta"[tiab]. The summary above synthesizes these.
- Fecal Incontinence: Etiology, Diagnosis, and Management.
Alavi K, Chan S, Wise P, et al. · J Gastrointest Surg · 2015Review
- Ultrasound-guided fine-needle aspiration of a rectal submucosal nodule.
Wang ZQ, Mani H, Lee IH, et al. · Diagn Cytopathol · 2020Case Reports
- Endoscopic and imaging appearance after injection of an ano-rectal bulking agent.
Papafragkakis H, Changela K, Bhatia T, et al. · World J Gastrointest Endosc · 2014Case Reports
- Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies.
Al-Bayati I, Saadi M, Elhanafi S, et al. · Am J Med Sci · 2017
- Endoscopic, Ultrasonographic, and Histologic Descriptions of Dextranomer/Hyaluronic Acid in a Case of Fecal Incontinence.
Irwin T, Snow AR, Orton TS, et al. · Case Rep Pathol · 2018Case Reports
- Migrated Bulking Material (Solesta) Presenting as a Vaginal "Cyst": Histopathologic and Chemical Analytical Features.
Zhu CS, Matz RN, Lewin-Smith M, et al. · Int J Gynecol Pathol · 2022Case Reports
- Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinence.
Franklin H, Barrett AC, Wolf R · Clin Exp Gastroenterol · 2016
- Dextranomer in stabilized sodium hyaluronate (Solesta®): in adults with faecal incontinence.
Hoy SM · Drugs · 2012Multicenter Study, Review
- Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulation after conservative therapy for the management of fecal incontinence.
Bernstein MA, Purdy CH, Becker A, et al. · Clin Ther · 2014Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code LNM.
- Deflux Injectable GelPalette Life Sciences · PMA 2016
- Macroplastique ImplantsUroplasty, LLC · PMA 2023
- Durasphere Injectable Bulking AgentCarbon Medical Technologies, Inc. · PMA 2026
- Coaptite Injectable ImplantMerz North America, Inc. · PMA 2024
- Contigen Bard Collagen ImplantAllergan, Inc. · PMA 2009
- Bard Tegress Urethral ImplantC.R. Bard, Inc. · PMA 2006
- Enteryx Procedure KitBoston Scientific Corp · PMA 2005
- Durasphere ExpCarbon Medical Technologies, Inc. · PMA 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.